Skip to main content

Advertisement

Log in

Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a vascular disrupting agent currently under phase II clinical trials in combination with cancer chemotherapy, in rats bearing chemically induced primary mammary tumours.

Methods

Tumours were induced in female Wistar rats by injection of N-nitroso-N-methylurea at 100 mg/kg subcutaneously. A clinically relevant single dose of DMXAA (1,800 mg/m2) was given to animals when tumours were measurable. Tumour volume, extent of necrosis and cytokine profiles were measured.

Results

Compared with the control group, DMXAA treatment significantly delayed tumour doubling time and extended the time from treatment to euthanasia. Four of five DMXAA-treated animals showed necrosis involving 3.7–41.2% of the area of the tumour section at 24 h compared with none of four control animals (P < 0.028, Chi-square test). Intratumoural levels of TNFα, IL-6, VEGF and IL-1α were increased 4 h after DMXAA treatment.

Conclusions

This study shows for the first time that DMXAA has significant in vivo antitumour activity against non-transplanted autochthonous tumours and in a host species other than the mouse.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siemann DW, Bibby MC, Dark GG et al (2005) Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11:416–420

    PubMed  CAS  Google Scholar 

  2. Kelland L (2005) Targeting established tumor vasculature: a novel approach to cancer treatment. Curr Cancer Ther Rev 1:1–9

    Article  Google Scholar 

  3. Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev 5:436–446

    CAS  Google Scholar 

  4. Baguley BC (2003) Antivascular therapy of cancer: DMXAA. Lancet Oncol 4:141–148

    Article  PubMed  CAS  Google Scholar 

  5. Siim BG, Lee AE, Shalal-Zwain S et al (2003) Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51:43–52

    Article  PubMed  CAS  Google Scholar 

  6. Wilson WR, Li AE, Cowan DS et al (1998) Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 42:905–908

    Article  PubMed  CAS  Google Scholar 

  7. Baguley BC, Wilson WR (2002) Potential of DMXAA combination therapy for solid tumors. Expert Rev Anticancer Ther 2:593–603

    Article  PubMed  CAS  Google Scholar 

  8. Rustin G, Bradley C, Galbraith S et al (2003) 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 88:1160–1167

    Article  PubMed  CAS  Google Scholar 

  9. Kestell P, Paxton JW, Rewcastle GW et al (1999) Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit. Cancer Chemother Pharmacol 43:323–330

    Article  PubMed  CAS  Google Scholar 

  10. Jameson MB, Thompson PI, Baguley BC et al (2003) Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 88:1844–1850

    Article  PubMed  CAS  Google Scholar 

  11. Zhou SF, Tingle MD, Kestell P et al (2002) Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo. Xenobiotica 32:87–107

    Article  PubMed  CAS  Google Scholar 

  12. McKeage MJ, Fong P, Jeffery M et al (2006) 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) in the treatment of refractory tumours: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 12:1776–1784

    Article  PubMed  CAS  Google Scholar 

  13. Woon ST, Reddy CB, Drummond CJ et al (2005) A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kB in murine and human cell lines. Oncol Res 15:351–364

    PubMed  CAS  Google Scholar 

  14. Russo J, Russo IH (1996) Experimentally induced mammary tumors in rats. Breast Cancer Res Treat 39:7–20

    Article  PubMed  CAS  Google Scholar 

  15. Field S, Burney IA, Needham S et al (1991) Are transplanted tumours suitable as models for studies on vasculature? Int J Radiat Biol 60:255–260

    PubMed  CAS  Google Scholar 

  16. Izumi Y, di Tomaso E, Hooper A et al (2003) Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts. Cancer Res 63:747–751

    PubMed  CAS  Google Scholar 

  17. Fenton BM, Lord EM, Paoni SF (2001) Intravascular HBO2 saturations, perfusion and hypoxia in spontaneous and transplanted tumor models. Int J Cancer 93:693–698

    Article  PubMed  CAS  Google Scholar 

  18. Sgadari C, Angiolillo AL, Cherney BW et al (1996) Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 93:13791–13796

    Article  PubMed  CAS  Google Scholar 

  19. Dinney CP, Bielenberg DR, Perrotte P et al (1998) Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-a administration. Cancer Res 58:808–814

    PubMed  CAS  Google Scholar 

  20. Carswell EA, Old LJ, Kassel RL et al (1975) An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci USA 72:3366–3670

    Article  Google Scholar 

  21. Watanabe N, Niitsu Y, Umeno H et al (1988) Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 48:2179–2183

    PubMed  CAS  Google Scholar 

  22. Manda T, Shimomura K, Mukumoto S et al (1987) Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity. Cancer Res 47:3707–3711

    PubMed  CAS  Google Scholar 

  23. Dvorak HF, Gresser I (1989) Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 81:497–502

    Article  PubMed  CAS  Google Scholar 

  24. Johnson CS, Chang MJ, Braunschweiger PG et al (1991) Acute haemorrhagic necrosis of tumours induced by interleukin-1-alpha—effects independent of tumor necrosis factor. J Natl Cancer Inst 83:842–848

    Article  PubMed  CAS  Google Scholar 

  25. Baban DF, Seymour LW (1998) Control of tumour vascular permeability. Adv Drug Deliv Rev 34:109–119

    Article  PubMed  CAS  Google Scholar 

  26. Joseph WR, Cao Z, Mountjoy KG et al (1999) Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 59:633–638

    PubMed  CAS  Google Scholar 

  27. Philpott M, Baguley BC, Ching LM (1995) Induction of tumour necrosis factor-a by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36:143–148

    PubMed  CAS  Google Scholar 

  28. Ching LM, Goldsmith D, Joseph WR et al (1999) Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 59:3304–3307

    PubMed  CAS  Google Scholar 

  29. Pang JH, Cao Z, Joseph WR et al (1998) Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor. Eur J Cancer 34:1282–1289

    Article  PubMed  CAS  Google Scholar 

  30. Cao Z, Baguley BC, Ching LM (2001) Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res 61:1517–1521

    PubMed  CAS  Google Scholar 

  31. Zhao L, Ching LM, Kestell P et al (2002) The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 87:465–470

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The work was supported by New Zealand Cancer Society and the Auckland Medical Research Foundation. We wish to thank Prof. Michael Dragunow for his helpful assistance in imaging analysis (http://www.health.auckland.ac.nz/pharmacology/discovery-1/).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark J. McKeage.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, J.J., Ching, LM., Goldthorpe, M. et al. Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. Cancer Chemother Pharmacol 59, 661–669 (2007). https://doi.org/10.1007/s00280-006-0321-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0321-7

Keywords

Navigation